NEW YORK - Protalix BioTherapeutics Inc. said yesterday that US regulators will review its experimental treatment for Gaucher disease on a fast-track basis and it aims to have data from a late-stage trial of the drug by October.By: Ransdell Pierson|Date: Aug 26, 2009

NEW YORK - Sepracor Inc. , a Marlborough, Mass., biotechnology company, yesterday suffered a double setback as its experimental depression drug failed a midstage study and US regulators halted two pediatric studies of its blockbuster Lunesta insomnia pill, sending shares down over 15 percent in after-hours trading.By: Ransdell Pierson|Date: Jul 2, 2009

...been unanimously approved by the boards of both companies and is expected to close in late August. (Reporting by Ransdell Pierson, Jessica Hall and Toni Clarke; Editing by Gary Hill and Carol Bishopric)By: Ransdell Pierson|Date: Jul 23, 2009

...2 billion to $23.7 billion. The company expects its acquisition of Schering-Plough to close in the fourth quarter. Merck shares were up $1.06 at $29.00. (Reporting by Ransdell Pierson; editing by John Wallace and Derek Caney)By: Ransdell Pierson|Date: Jul 21, 2009